255 documents

Read All
02:21 , Mar 29, 2019 |  BC Innovations  |  Targets & Mechanisms

AACR moves in a myeloid direction

Myeloid cells are showing up everywhere at this year’s AACR conference, suggesting the research community is rapidly expanding the ways it can harness the cell types to improve cancer immunotherapy responses. One of those ways...
Read More
22:06 , Jul 25, 2017 |  BC Innovations  |  Distillery Therapeutics

Cardiovascular

INDICATION: Heart failure In vitro and cell culture studies identified a methyltriazole-based GRK2 inhibitor that could help treat heart failure. Previous studies have shown GRK2 levels are elevated in cardiac tissue of heart failure patients....
Read More
20:33 , Jul 25, 2017 |  BC Innovations  |  Distillery Therapeutics

Endocrine / Metabolic

INDICATION: Obesity In vitro and mouse studies suggest a modified NMU peptide that agonizes NMUR2 could help treat obesity. The agonist consisted of a PEGylated, eight amino acid from the NMU C-terminus containing a napthylalanine...
Read More
17:41 , Mar 17, 2017 |  BC Week In Review  |  Company News

Takeda, Scohia deal

Takeda will spin out eight candidates into newco Scohia to treat diabetes and renal and cardiovascular diseases. Takeda partnered with drug distributor Medipal Holdings Corp. (Tokyo:7459, Tokyo, Japan) and public-private partnership Innovation Network Corp. of...
Read More
22:50 , Mar 15, 2017 |  BC Extra  |  Company News

Takeda spinning out eight candidates to newco Scohia

Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) said it will spin out eight diabetes, renal and cardiovascular disease candidates into newco Scohia Pharma Inc. (Fujisawa, Japan). Takeda partnered with drug distributor Medipal Holdings Corp. (Tokyo:7459) and public-private...
Read More
07:00 , Aug 12, 2013 |  BioCentury  |  Strategy

FibroGen's globetrotting

Seven years after its last major deal, FibroGen Inc. has now carved up worldwide rights to FG-4592 via its new deal with AstraZeneca plc . A key task for FibroGen is now to execute in...
Read More
07:00 , Jun 17, 2013 |  BioCentury  |  Strategy

Externalizing Astellas

With a stocked late-stage pipeline, Astellas Pharma Inc. has decided to restructure its R&D and give more attention to finding early stage programs by looking outside. The Japanese pharma will eliminate much of its bricks-and-mortar...
Read More
08:00 , Mar 8, 2010 |  BioCentury  |  Strategy

OSI's Last Stand

OSI Pharmaceuticals Inc. has made two strategic decisions in the last five years that investors didn't like. As a result, it would not be surprising if they refuse to back the company's independence following last...
Read More
08:00 , Dec 21, 2009 |  BioCentury  |  Finance

Ebb & Flow

The 2004 merger of Fujisawa Pharmaceutical Co. Ltd. and Yamanouchi Pharmaceutical Co. Ltd. to form Astellas Pharma Inc . (Tokyo:4503) has led to big payoffs in the last two weeks for Calixa Therapeutics Inc. and...
Read More
08:00 , Dec 14, 2009 |  BioCentury  |  Finance

Ebb & Flow

Investors in oncology company Gloucester Pharmaceuticals Inc. are looking at a 3.5X-6.5X return on an acquisition by Celgene Corp. (NASDAQ: CELG), making it a model for how to execute in-licensing and keep costs under control....
Read More